Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Brokerages

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has been given a consensus recommendation of “Hold” by the nine ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $14.00.

A number of analysts have recently issued reports on the stock. Needham & Company LLC cut their target price on shares of Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. Truist Financial set a $8.00 target price on shares of Bicycle Therapeutics in a research note on Tuesday, March 17th. Royal Bank Of Canada cut their target price on shares of Bicycle Therapeutics from $11.00 to $7.00 and set a “sector perform” rating for the company in a research note on Wednesday, March 18th. Morgan Stanley cut their target price on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 8th. Finally, Jefferies Financial Group restated a “buy” rating and set a $12.00 target price on shares of Bicycle Therapeutics in a research note on Thursday, April 30th.

Insider Activity

In other news, CEO Kevin Lee sold 5,967 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $4.91, for a total transaction of $29,297.97. Following the completion of the sale, the chief executive officer owned 613,029 shares in the company, valued at approximately $3,009,972.39. This trade represents a 0.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 9,992 shares of company stock worth $49,363. Company insiders own 22.90% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of BCYC. Assetmark Inc. raised its stake in Bicycle Therapeutics by 74.9% in the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after purchasing an additional 1,552 shares in the last quarter. Clearstead Advisors LLC raised its stake in Bicycle Therapeutics by 234.2% in the 4th quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock worth $33,000 after purchasing an additional 3,262 shares in the last quarter. Royal Bank of Canada raised its stake in Bicycle Therapeutics by 35.5% in the 1st quarter. Royal Bank of Canada now owns 14,470 shares of the company’s stock worth $67,000 after purchasing an additional 3,788 shares in the last quarter. Brooklyn Investment Group acquired a new stake in Bicycle Therapeutics in the 4th quarter worth about $69,000. Finally, Ausdal Financial Partners Inc. acquired a new stake in Bicycle Therapeutics in the 2nd quarter worth about $70,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Stock Performance

NASDAQ BCYC opened at $4.00 on Friday. The firm has a 50-day moving average of $4.62 and a 200-day moving average of $5.54. The stock has a market cap of $278.89 million, a PE ratio of -1.27 and a beta of 1.54. Bicycle Therapeutics has a 52-week low of $3.95 and a 52-week high of $9.18.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, April 30th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.25). The company had revenue of $0.89 million for the quarter, compared to analyst estimates of $7.50 million. Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%. As a group, analysts predict that Bicycle Therapeutics will post -1.97 EPS for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.